Frontline immune checkpoint inhibitors in patients ≥ 90 years with advanced urothelial cancer: a single center experience.

Evangelia VlachouBurles Avner Johnson ⅢElizabeth GuancialKara A LombardoJean Hoffman-Censits

Published in: The Canadian journal of urology (2024)

Our experience in a small cohort of patients ≥ 90 years indicate that ICIs are well tolerated and effective for the treatment of advanced urothelial carcinoma in this patient population.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
peritoneal dialysis
squamous cell carcinoma
high grade
case report
papillary thyroid
childhood cancer
urinary tract